Alivus Life Sciences Q3 FY26 Revenue at ₹672.88 Crore, Profit at ₹150.26 Crore
Alivus Life Sciences reported Q3 FY26 results with total income of ₹686.82 crore and profit after tax of ₹150.26 crore. For the nine months ended Dec 31, 2025, total income was ₹1,900.35 crore and profit after tax was ₹401.82 crore. EPS for the quarter was ₹12.25.
The results show financial performance for the quarter and nine months, which is material information for investors. The exceptional item related to labor codes is also a significant factor.
The company reported an increase in profit for the quarter and nine months compared to the previous year, despite an exceptional item related to new labor codes.
Alivus Life Sciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved these results in a meeting held on January 22, 2026, which commenced at 12:25 p.m. and concluded at 1:25 p.m.
For the third quarter ended December 31, 2025, Alivus Life Sciences reported total income of ₹6,868.17 million (₹686.82 crore) and a profit after tax of ₹1,502.61 million (₹150.26 crore). This compares to a profit after tax of ₹1,369.60 million (₹136.96 crore) in the same quarter of the previous year. The company also reported earnings per share (EPS) of ₹12.25 for the quarter.
For the nine months ended December 31, 2025, the total income stood at ₹19,003.48 million (₹1,900.35 crore), with a profit after tax of ₹4,018.22 million (₹401.82 crore). The EPS for the nine-month period was ₹32.76.
An exceptional item was recorded due to the statutory impact of new labor codes, amounting to ₹256.57 million (₹25.66 crore), which affected the profit before tax calculation for the quarter. The company has provided a limited review report from its statutory auditor, Walker Chandiok & Co. LLP, who expressed an unmodified conclusion. The financial results are also available on the company's website.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.